Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
36 hedge funds and large institutions have $87.7M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 35 → 36 (+1)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
15% less capital invested
Capital invested by funds: $104M → $87.7M (-$16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$4.62M |
| 2 |
Walleye Capital
New York
|
+$1.18M |
| 3 |
Barclays
London,
United Kingdom
|
+$912K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$227K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.01M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$1.94M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$309K |
| 4 |
Two Sigma Investments
New York
|
-$216K |
| 5 |
Morgan Stanley
New York
|
-$191K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
26
Schonfeld Strategic Advisors
New York
| $81K | +$33.8K | +7,500 | +54% |
|
27
Norges Bank
Oslo,
Norway
| $67.3K | -$71.2K | -15,800 | -47% |
|
|
28
Morgan Stanley
New York
| $47K | -$191K | -42,335 | -77% |
|
29
Charles Schwab
San Francisco,
California
| $47K | – | – | – |
|
30
Goldman Sachs
New York
| $39K | -$892 | -198 | -2% |
|
31
UBS Group
Zurich,
Switzerland
| $9K | +$11K | +2,442 | +9,768% |
|
32
Fidelity Investments
Boston,
Massachusetts
| $8K | +$9.75K | +2,163 | New |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| $7K | +$7.17K | +1,590 | +828% |
|
|
34
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
| – | -$309K | -68,600 | Closed |
|
|
EGM
35
Engineers Gate Manager
New York
| – | -$51K | -11,273 | Closed |
|
36
Bank of America
Charlotte,
North Carolina
| – | -$19K | -4,297 | Closed |
|
37
Simplex Trading
Chicago,
Illinois
| – | -$14 | -3 | -2% |
|
38
Wells Fargo
San Francisco,
California
| – | +$5 | +1 | +0.9% |
|
39
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$419 | +93 | New |
|
STSA Hedge Fund Activity: Q1 2022 in Review
36 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q1 2022, worth a combined $87.7M — down 15% from $104M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new STSA positions and 3 closed out — a net gain of 1 holder — while 11 added to existing stakes and 12 trimmed.
The largest buyer was Samlyn Capital, adding an estimated $4.62M. The largest seller was Citadel Advisors, cutting an estimated $4.01M.
- 36 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q1 2022, up from 35 in Q4 2021.
- Funds reported $87.7M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 15% quarter-over-quarter.
- 4 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 3 closed out, a net change of +1 holder.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Samlyn Capital, an estimated $4.62M added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Citadel Advisors, an estimated $4.01M sold.
Based on aggregated 13F filings for Q1 2022.